Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Boston Therapeutics and Advance Pharmaceutical report topline data from study of BTI-320

Oct. 7, 2016

Alnylam Pharmaceuticals discontinues development of revusiran

Oct. 6, 2016

DTX-401 named FDA orphan drug for treating glycogen storage disease type Ia

Oct. 6, 2016

New company Kymo Therapeutics formed to advance KMO inhibitors

Oct. 6, 2016

Lrp6 may be a new PTH-activated aNAC target gene

Oct. 5, 2016

Slit3 shows potential as a therapeutic target in metabolic bone diseases

Oct. 5, 2016

Bone Therapeutics reports promising data on Allob from phase IIa spinal fusion trial

Oct. 5, 2016

Once-daily Belviq XR available in U.S. for chronic weight management

Oct. 4, 2016

Zurampic 200 mg tablets now available in U.S. for patients with uncontrolled gout

Oct. 4, 2016

CohBar advances two drug candidates into IND-enabling activities

Oct. 4, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 10, 2026.
Hengrui discovers new Nav1.8 blockers
BioWorld Science
Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
Hematopoietic stem cell research points to leukemia’s early roots
BioWorld
Hematopoietic stem cell research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...
Korsana boosts Alzheimer’s work with reverse merger, $380M financing
BioWorld Science
Just over a month after emerging from stealth and disclosing a $150 million series A, Korsana Biosciences Inc. is making the leap to the public market via a...